Physician profile
Ryan Bruce Thorpe
NPI 1568880995
$3,605.19
in general payments reported to CMS, 2019-2025
23 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $301 · 2021: $684 · 2022: $657 · 2023: $601 · 2024: $780 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,848.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,232.44 | 2019-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $475.63 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $432.36 | 2021-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $327.42 | 2021-2025 | |
| Genzyme Corporation | $222.87 | 2020-2025 | |
| Ucb, INC. | $112.28 | 2021-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.66 | 2023-2025 | Spevigo, Cyltezo |
| Galderma Laboratories, L.P. | $90.21 | 2019-2025 | Nemluvio |
| Incyte Corporation | $88.30 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $86.14 | 2022-2024 | Adbry |
| Janssen Biotech, INC. | $77.94 | 2021-2025 | Tremfya |
| Vyne Pharmaceuticals INC. | $71.53 | 2021 | |
| Amgen INC. | $58.50 | 2020-2022 | |
| Lilly USA, LLC | $42.14 | 2019-2024 | Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $40.70 | 2023 | Sotyktu |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pierre Fabre Pharmaceuticals, INC. | $29.79 | 2023-2024 | Hemangeol |
| Helsinn Therapeutics (U.S.), INC. | $27.77 | 2022 | |
| Nobelpharma America, LLC | $23.72 | 2025 | |
| Arcutis Biotherapeutics, INC. | $16.80 | 2024 | Zoryve |
| Genentech USA, INC. | $16.75 | 2021 | |
| Acera Surgical, INC. | $13.32 | 2022 | |
| Kyowa Kirin, INC. | $12.90 | 2021 | |
| Organon LLC | $11.02 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Thorpe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.